Compensation award — excluded from discretionary-purchase analysis.
Traded Oct 1, 2025 · Filed Oct 2, 2025
A big owner of Eli Lilly sold $19.2M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$19,178,427
Shares × reported transaction price
55 days after results of Aug 7, 2025, 29 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $825.42 on Oct 1, 2025, 32% above its 52-week low and 11% below its high, after a 17% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $932.06 (Oct 11, 2024), 65% of the way up, from 250 adjusted closes. 30 trading days earlier: $703.21 on Aug 19, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Inluriyo on Sep 25, 2025, 6 days before this trade.
New drug application approved. Active ingredient: Imlunestrant Tosylate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -0.8% | -2.4% | +1.7% |
| 30 days | +6.8% | +2.1% | +4.6% |
| 90 days | +28.6% | +2.1% | +26.5% |
| 180 days | +13.7% | -2.1% | +15.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.